24 completed, 3 terminated, 2 recruiting, 2 withdrawn. 14 Phase 3, 8 Phase 1, 7 Phase 4, 5 Phase 2.
Follow Metformin XR: new trials by email Literature Review of Metformin XR trials Research Report on Metformin XR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy Metformin XR, Celecoxib, Valsartan - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Myopharm Limited | 48 | 2026-09-01 | 2026-07-08 |
| Effect of NAE on Polycystic Ovarian Syndrome (PCOS) Herbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg - Polycystic Ovarian Syndrome (PCOS), Infertility | Phase 1 | Completed | Jinnah Sindh Medical University | 116 | 2025-04-10 | 2026-06-22 |
| Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome Herbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg - Polycystic Ovarian Syndrome (PCOS), Herbal Medicine | Phase 1 | Completed | Jinnah Postgraduate Medical Centre | 116 | 2025-02-22 | 2026-06-23 |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes Metformin XR, Placebo - Prediabetic State, Atherosclerosis | Phase 4 | Recruiting | VA Office of Research and Development | 7410 | 2023-04-03 | 2025-12-17 |
| Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Metformin XR, Control - Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Recruiting | The University of Queensland | 1174 | 2022-11-29 | 2026-03-31 |
| Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Metformin Extended Release Oral Tablet - Breast Cancer Stage, Insulin Resistance | Phase 4 | Withdrawn | Woman's | 2022-09-01 | 2023-07-06 | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant Alpelisib, Fulvestrant, Metformin XR - Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 2 | 2022-04-06 | 2024-10-09 |
| Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction Metformin, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Wake Forest University Health Sciences | 86 | 2022-01-04 | 2026-06-10 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Metformin XR, Placebo - Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 60 | 2021-04-27 | 2026-02-09 |
| A Study of LY900020 in Healthy Chinese Participants LY900020, Metformin XR, Atorvastatin - Healthy | Phase 1 | Completed | Eli Lilly and Company | 32 | 2019-11-29 | 2020-03-03 |
| Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity Dapagliflozin, Dapagliflozin plus Metformin XR, Metformin XR - Obesity | Phase 4 | Unknown | University of Guadalajara | 33 | 2019-07-30 | 2023-05-23 |
| Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma Metformin XR, Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | University of Campinas, Brazil | 28 | 2017-01-01 | 2026-07-17 |
| Randomized Sitagliptin Withdrawal Study (MK-0431-845) Sitagliptin, Placebo to sitagliptin, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 746 | 2016-05-09 | 2019-02-25 |
| Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes Metformin IR, Metformin XR - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 532 | 2014-12-01 | 2017-01-24 |
| PCOS Treatment Using DLBS3233, Metformin, and Combination of Both DLBS3233, Metformin XR, Placebo metformin - Polycystic Ovary Syndrome (PCOS), Insulin Resistance | Phase 3 | Completed | Dexa Medica Group | 186 | 2014-10-01 | 2019-05-28 |
| Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Glipizide XL, Saxagliptin + Metformin XR, Metformin XR - Diabetes Mellitus Type 2, Hyperglycemia | Phase 4 | Completed | Cook County Health | 100 | 2014-09-09 | 2023-06-26 |
| A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors Metformin XR, Delayed Metformin, Sirolimus - Breast Neoplasms, Lung Neoplasms | Phase 1 | Completed | University of Chicago | 24 | 2014-04-01 | 2019-04-22 |
| Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis Metformin XR, Saxagliptin, Saxagliptin-Metformin XR - Polycystic Ovary Syndrome, Disorder of Glucose Regulation | Phase 3 | Completed | Woman's | 38 | 2014-03-01 | 2017-06-28 |
| Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes Metformin XR, Metformin IR, Placebo matching with Metformin XR - Type 2 Diabetes Mellitus | Phase 4 | Completed | Bristol-Myers Squibb | 1736 | 2013-06-20 | 2019-11-29 |
| A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Janssen Research & Development, LLC | 1186 | 2013-06-04 | 2017-07-11 |
Showing 20 of 34. Sign in to see all of them.
Diabetes Mellitus, Type 2 (17) · Polycystic Ovary Syndrome (6) · Diabetes Mellitus (4) · Breast Neoplasms (3) · Infertility (3) · Insulin Resistance (3) · Metabolic Diseases (3) · Hyperglycemia (2) · Atherosclerosis (1) · Cerebrovascular Disorders (1) · Coronary Artery Disease (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Failure (1) · Hereditary Sensory and Autonomic Neuropathies (1)
AstraZeneca (10) · Bristol-Myers Squibb (2) · Dexa Medica Group (2) · Merck Sharp & Dohme LLC (2) · Woman's (2) · Cook County Health (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Janssen Research & Development, LLC (1) · Jinnah Postgraduate Medical Centre (1) · Jinnah Sindh Medical University (1) · Merck KGaA, Darmstadt, Germany (1) · Myopharm Limited (1) · Novartis Pharmaceuticals (1)
United States (20) · Mexico (8) · Puerto Rico (5) · South Korea (4) · Brazil (3) · Canada (3) · Romania (3) · Russia (3) · South Africa (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Czechia (2) · Germany (2) · Hungary (2)
Ambika Babu, MD,MS (1) · Andon Hestiantoro, dr., SpOG(K) (1) · Andrew Mallett, MBBS, PhD (1) · Arsana Wiyasa IW, Dr. dr., SpOG-K (1) · Boaz Hirschberg, MD (1) · Catherine R Marinac, PhD (1) · Charles Czank (1) · Cynthia Harper-Weinstein (1) · Dalane W. Kitzman, MD (1) · Eddy Suparman, Prof. Dr. dr., SpOG-K (1) · Ericka Seidemann, MA (1) · Gregory G. Schwartz, PhD MD (1)
PMID 26894924, PMID 17287476, PMID 18000088, PMID 19509098, PMID 20826578, PMID 21645894, PMID 21819160, PMID 21832111, PMID 22192246, PMID 22413962, PMID 22617579, PMID 23468941, PMID 25324541, PMID 25352655, PMID 26036903, PMID 26354094, PMID 26786577, PMID 28228317, PMID 30304106, PMID 30393950, PMID 31364269, PMID 34779103, PMID 37424700, PMID 38154770, PMID 38837240, PMID 39033369, PMID 39173182, PMID 39356039, PMID 40855441, PMID 41348481, PMID 41385299
2014 (1), 2015 (1), K22CA251648 (1), U01AG076928 (1)